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Abstract 
Dry Powder Inhaler (DPI) could offer a propellant-free, easy-to-use powder form ensuring 
better stability than liquid dosage forms. Therefore the development of traditional carrier-based 
and carrier-free new generation systems is a determinative factor in the field of DPI 
formulation. The purpose of our research work was to combine these two systems, utilizing 
their beneficial properties to produce a novel pulmonary drug delivery system containing 
ciprofloxacin hydrochloride (CIP). Co-spray drying, surface smoothing and the preparation of 
an interactive physical mixture were applied as the technological procedures of sample 
preparation. The carrier-based and carrier-free formulations, as well as the developed novel 
product were compared to each other. Structural investigations were made by X-ray powder 
diffraction and micrometric properties (habit, bulk density) were determined. Particle 
interactions were also evaluated to investigate surface free energy, cohesive-adhesive forces, 
and spreading coefficient. In vitro aerodynamic properties (mass median aerodynamic 
diameter, fine particle fraction (FPF) and emitted dose of DPIs were measured using Andersen 
Cascade Impactor. A novel in silico Stochastic Lung Model was also used to quantify the 
amount of particles deposited at the target area. The novel-formulated composition presented 
amorphous spherical particles with an average size of about 2 µm. The in vitro aerodynamic 
investigations showed a variance in FPF as a function of formulation method (carrier-based: 
24%, carrier-free: 54% and applying the novel combination method: 63%). The in silico 
deposition results were in line with the in vitro measurements and yielded increased lung doses 
for the sample prepared by the combined technology. This novel DPI formulation provides an 
opportunity for a more effective therapy with deeper deposition of CIP. 
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1. Introduction 
Pulmonary drug administration enables to target drugs directly to the lung for local or systemic 
therapy. DPI compositions can be divided into two main categories, conventional carrier-based 
and carrier-free (new generation) systems (Benke et al., 2017). The marketed products belong 
to the traditional carrier-based formulations, applying a large carrier (e.g. lactose) and a 
micronized active pharmaceutical ingredient (Lee et al., 2018, Peng et al., 2016). Using a carrier 
is advantageous for active compounds with strong cohesive properties that have a positive effect 
on the flow properties of the product, the dosage of a small amount of drug can be refined or 
the taste of the carrier in the oral cavity during inhalation confirms the successful use of the 
product in the patient. However, most of these marketed products still have low pulmonary 
deposition values (~ 20-30% FPF, fine particle fractionation value), hence only a small 
percentage of the active ingredient can reach the proper lung segments because a large mass 
will be deposited in the upper respiratory tract. Only the modification of interparticle interaction 
(Tüske, 2005) (decrease of cohesive-adhesive forces by technological methods) could result in 
higher lung deposition. The role of the carrier and special additives applied in the designing 
phase is to prepare particles easy to handle during manufacturing and to provide an enhanced 
aerosolization property for inhalation (Velaga et al., 2018; Della Bella et al., 2017). Inhalac® 
series (different-sized lactose monohydrate, MEGGLE Group, Wasserburg, Germany) offer 
high quality drug transport to the lung (Pilcer et al., 2012). Lactose particles entering the lungs 
are rapidly absorbed, then metabolized and finally excreted in the urine. The processing of DPI 
formulation with a minimum concentration of magnesium stearate (MgSt) is an effective means 
of improving the de-agglomeration and aerosolization of cohesive powders (Coccini et al., 
2012). Making a thin film with this excipient could produce better aerosolization properties. It 
could be applied in a wide range between 0.001-10.0 w/w %. In the lower segments of the lung, 
only an insignificant amount of MgSt is released, which does not have negative effects and 
therefore many marketed products have a MgSt content (Palistra, 2008; Keller and Müller-
Walz, 2003). 
In the case of carrier-free DPI systems, the application of large carriers can be avoided with the 
use of special excipients and technologies (e.g. co-spray drying) (Chvatal et al., 2017; Yang et 
al., 2015). These systems yield around 50-60 % FPF results due to the apparent high cohesive 
properties between the active ingredient’s particles (Kadota et al., 2015). These formulations 
involve the usage of different amino acids (e.g. L-leucine) and polymers (e.g. polyvinyl alcohol 
or polyvinylpyrrolidone) (Pilcer and Amighi, 2010). The most important advantages of these 
novel formulations are their low density, improved aerodynamic properties and higher lung 
deposition (Healy et al., 2014). However, the main problem with the microparticles is that they 
stick to each other because of their high surface free energy. Overcoming this cohesive nature 
included the incorporation of large amounts of lipophilic adjuncts (such as the mixture of 
cholesterol and phospholipids e.g. sodium stearate) (Buttini et al., 2012). The preliminary 
analysis of the toxicity effect of sodium stearate on A549 lines showed that the adjunct, in the 
concentration (maximum 3 w/w %) used, had no effect on cell viability over a 24h period 
compared to particles of pure tobramycin. 
The use of antibiotics in the treatment of pulmonary fibrosis has long been known since Abbot 
Laboratories developed the inhaler (Aerohalor) containing penicillin powder in 1948. The most 
common treatment for bacterial respiratory infections is currently the oral administration of 
high doses of single or combined antibiotics, which may have serious side effects. With the 
development of antibiotic-containing DPI systems, the local treatment of these diseases is 
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possible. Thus, high levels of the active substance can be achieved in the lung tissue, smaller 
doses are sufficient for oral therapy, leading to reduced systemic antibiotic exposure and lower 
toxicity. Ciprofloxacin hydrochloride (CIP) belongs to fluoroquinolones, it has a 6-fluoro-7-
piperazinyl group, which is responsible for its antibacterial effectiveness (Gram- and Gram+ 
microorganisms) (Karimi et al., 2016). CIP is a major advance in the treatment of 
bronchopulmonary infection in patients with cystic fibrosis and chronic obstructive lung 
disease. At present, tobramycin and aztreonam are the only inhaled antibiotics on the market. 
CIP is also a potential pharmacon for DPI formulation (it is in Phase III as a PulmoSphere® 
system) (Stass et al., 2008). Therefore it is important to study its newer DPI formulations. 
The aim of our work is to develop a novel DPI system using combined technology to formulate 
CIP containing DPI samples. It was important that all of the formulated DPI samples (carrier-
based, carrier-free and novel combined method) will be fulfilling the requirements of effective 
pulmonary drug delivery (micronized particles with low density for deep lung deposition). Our 
goal is to exceed the FPF values of the carrier-based and carrier-free DPIs and to find 
correlations between the interparticle interactions and the lung exposure results and to suggest 
a novel DPI formulation for pulmonary application of CIP. 
2. Materials and methods  
2.1 Materials 
Micronized ciprofloxacin hydrochloride (µCIP), a fluoroquinolone-type antibiotic, (D50: 5.09 
µm) was kindly supplied by Teva Pharmaceutical Works Ltd. (Debrecen, Hungary). Lactose 
monohydrate, Inhalac® 70 (IH 70) (D50: 215.00 µm) (MEGGLE Group, Wasserburg, 
Germany) was used as a carrier base. Magnesium stearate (MgSt) was applied as a surface 
modifier (Sigma-Aldrich, Budapest, Hungary) (D50: 6.92 µm). Sodium stearate (NaSt) (Alfa 
Aesar, Heysham, United Kingdom) was used for habit modification. 
2.2 Methods 
2.2.1 Preparation of dry powder formulation 
Figure 1. presents the procedures which were used for carrier-based, carrier-free and their 
combined method for DPI preparation.  
First, we applied a well-known formulation method. According to the preliminary experiments, 
a large size Inhalac® type, IH 70 was chosen for the carrier-based formulation. These samples 
were prepared by mixing (Turbula System Schatz; Willy A. Bachofen AG Maschinenfabrik, 
Basel, Switzerland) using 1:10 drug : IH70 ratio (Benke et al., 2017) at 60 rpm for 30 minutes.  
The carrier-free formulation applied a co-spray-drying method with NaSt and the use of 30% 
of EtOH as the solvent phase to modify the habit of CIP. CIP solution to be spray-dried was 
prepared by mixing a 70 g of CIP containing aqueous solution (1.5 w/v%) with a 30 g of NaSt 
(0.0175 % w/v ) containing alcoholic solution applying 30°C. Finally, the prepared solid 
samples had 99.5 % of CIP and 0.5% of NaSt content. The spray drying procedure was carried 
out using a Büchi B-191 apparatus (Mini Spray Dryer, Büchi, Switzerland). The drying 
parameters were adjusted as follows, based on our previous experiments, see Table 1. (Pomázi 
et al., 2014).  
A combination of these two methods completed with surface smoothing of IH70 by MgSt 
(modification of the carrier’s surface and blending with a co-spray dried CIP system) resulted 
in the novel DPI formulation. The surface modification was made by 2 % of MgSt with mixing 
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for 4 h in a Turbula mixer. The carrier-free formulation containing 99.5 % of CIP and 0.5 % 
NaSt was prepared by spray drying then mixing for 30 minutes with IH70_MgSt as modified 
carrier in a 1:10 ratio as a combination method (see Table 1).   
 
Figure 1. Preparation protocol for different types of DPI formulations 
Table 1. focuses on and presents the selected compositions and Table 2. their process 
parameters as regards carrier-based, carrier-free and novel combined formulations. 
Table 1. Composition of the products 
 1, Carrier-based DPI 
(µCIP+IH70) 
2, Carrier-free DPI 
(CIP_0.5NaSt_spd) 
3, Novel DPI formulation 
(CIP_0.5NaSt_spd+IH70_MgSt) 
Compositions CIP-1.05 g 
 
 
IH70-10.50 g 
 
CIP-1.05 g 
NaSt-0.00525 g 
30 % EtOH- ad 100 g 
 
CIP-1.05 g 
NaSt-0.00525 g 
30% EtOH- ad 100 g 
 
+ 
 
IH70-10.32 g 
MgSt-0.232 g 
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Table 2. Process parameters of the products 
 1, Carrier-based DPI 
(µCIP+IH70) 
2, Carrier-free DPI 
(CIP_0.5NaSt_spd) 
3, Novel DPI formulation 
(CIP_0.5NaSt_spd+IH70_MgSt) 
Process 
parameters 
- blending- 0.5h 
(Turbula) 
- spray drying-
inlet/outlet temp: 130/78 
°C aspirator- 
75 %       air flow-
600L/min      feed 
pump- 5 % (Büchi) 
- surface modification-mixing 4h 
(Turbula) 
- spray drying- 130/78 °C 
aspirator-75%                              
air flow-600 L/min                    
feed pump- 5 % (Büchi) 
- blending-mixing 0.5 h (Turbula) 
 
2.2.2 X-ray powder diffraction (XRPD) 
The solid state form of the formulations was characterized by a BRUKER D8 Advance X-ray 
powder diffractometer (Bruker AXS GmbH, Karlsruhe, Germany) with Cu K λI radiation (λ = 
1.5406 Å) and a VÅNTEC-1 detector. The powder samples were scanned at 40 kV and 40 mA, 
with an angular range of 3° to 40° 2θ, at a step time of 0.1s and a step size of 0.01°.  
2.2.3 Micrometric properties 
2.2.3.1 Scanning electron microscopy (SEM) 
Scanning electron microscopy (SEM) (Hitachi S4700, Hitachi Scientific Ltd., Tokyo, Japan) 
was applied for the control of the morphology at 10 kV. The samples were coated by gold-
palladium (90 seconds) with a sputter coater (Bio-Rad SC 502, VG Microtech, Uckfield, UK) 
using an electric potential of 2.0 kV at 10 mA for 5 min. The air pressure was 1.3–13.0 MPa. 
2.2.3.2 Particle size and distribution 
The particle size of the samples was determined by laser diffraction (Malvern Mastersizer 
Scirocco 2000; Malvern Instruments Ltd., Worcestershire, UK). The dispersion medium was 
air for the characterized microparticles. The particle size distribution was characterized by the 
D(0.1), D(0.5), and D(0.9) values and the specific surface area.  
2.2.3.3 Determination of bulk density 
The bulk density of the samples was determined using a 5 ml tared graduated cylinder, filled 
with powder. After direct mass and volume measurement, the following relationship was 
applied: mass/volume. 
2.2.4 Interparticle interactions 
After the determination of the contact angle, surface free energy and polarity could be 
calculated. Around 0.15 g of the sample on 1 ton hydraulic press (Perkin Elmer hydraulic press, 
Waltham, USA) was pressed to pastille. Then the surface of the pastilles was dripped with polar 
and non-polar solvents. The contact angle was detected for 30 sec with Dataphysics OCA 20 
apparatus (Dataphysics Inc. GmbH, Germany), then the Wu-correlation was used.  
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The surface free energy of the material (  is defined as the free energy change that occurs 
when the surface is increased one unit. It consists of two parts: a disperse part ( ) and a polar 
part ( ), so the following formula could be used for calculation . The solvents were 
distilled water (γp=50.2 mN/m, γd=22.6 mN/m) and diiodomethane (γp=1.8 mN/m, γd=49 
mN/m). 
If the surface free energy (  and the polar component ( ) are known, the polarity of the 
samples can be determined according to the following equation / )*100. 
The work of cohesion is determined from the surface free energy: 
Wc = 2*  
 
The work of adhesion (Wa) is equal numerically to the energy that arises when two surfaces 
come into contact [92-94]:  
 
The force of adhesion was calculated by Derjaguin hypothesis (Fadh) [18]: 
 
where RA and RB are the radius of particle A and B, and the adhesive interaction was measured 
between them. R was determined during particle size analyses (D[0.5] / 2). 
The spreading coefficient (S12) shows the probability of one material (1) on the surface of the 
other material (2). It is used to characterize the distribution in two-component systems. This is 
a dimensionless number. The spread is more favourable and energy-efficient if the coefficient 
is a positive value and the number is larger. In our case, the spreading of the active ingredient 
can be characterized on the surface of the large substrate. The coefficient can be calculated with 
the following equations: 
 
 
where γd is the disperse part of the surface free energy and γp is the polar part of the surface free 
energy and γ is the total surface free energy of the components whose is spread on the other 
component (Tüske, 2005). 
2.2.5 In vitro-In silico aerodynamic deposition 
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2.2.5.1 In vitro deposition by Andersen Cascade Impactor 
In the field of pharmaceutical industry, the Andersen Cascade Impactor is a vertical equipment 
most generally used for the in vitro testing of the aerodynamic properties of inhaled DPIs. It 
complies with the specifications laid down in Ph. Eur. 2.9.18 (European Pharmacopoeia, 2015). 
The standard Andersen Cascade Impactor is designed for use with a flow rate at 28.3 L/min by 
a vacuum pump (High-capacity Pump Model HCP5, Critical Flow Controller Model TPK, 
Copley Scientific Ltd., Nottingham, UK). The actual flow rate through the impactor was 
detected by a mass flow meter (Flow Meter Model DFM 2000, Copley Scientific Ltd., 
Nottingham, UK) for each run. Its 8 stages are available for the particle size collection (Wong 
et al., 2010) where particles deposited at stages 2–5 are in the size range of 4.7 – 1.1 µm suitable 
for effective inhalation. The stages were coated with a 1% m/m mixture of Span® 80 and 
cyclohexane to simulate pulmonary adhesive circumstances, in order to allow for the 
attachment of floating particles and to imitate the surface humidity of the airways. Three 
parallel measurements were done, each time using hard gelatine capsules (transparent, size 3, 
Capsugel, Germany) to be ‘inhaled’ at the appropriate flow rate. Each capsule contained 
different amounts of powder sample equalling 10 mg of CIP, which is 10% of the oral dose as 
recommended. A Breezhaler® (Novartis) as DPI device was used for the inhalations. The 
inhaler, the mouthpiece, the induction port and each of the eight stages were washed out with 
distilled water to collect the deposited CIP. The drug concentration was quantified by an 
Ultraviolet–visible spectrophotometer (ATI-UNICAM UV/VIS Spectrophotometer, 
Cambridge, UK) at 276 nm. Fine particle fraction (FPF), mass median aerodynamic diameter 
(MMAD) and emitted dose (ED) were determined to characterize the deposition profile of the 
prepared DPI. The FPF (particles <5 µm) is representative of those particles that have a high 
probability of penetrating into the bronchial region and (particles <3 µm) deposit in the deep 
lung. The MMAD corresponds to the diameter of the particles deposited in the impactor for 
which 50% w/w of particles have a lower diameter and 50% w/w have a higher diameter (Parlati 
2008). ED is the dose (mg) which leaves the device and it is calculated by weight differences 
of the inhaler device before and after drug delivery. 
2.2.5.2 In silico stochastic model 
The newest version of the Stochastic Lung Model (SLM) (Koblinger and Hofmann, 1990) has 
been applied to quantify the amount of inhaled drug depositing in the upper airways and in the 
lungs. Regional deposited dose fractions were defined as the mass of drug deposited in a given 
region (extrathoracic or lungs) expressed as a percent of the mass of drug metered in the capsule. 
The deposition was modelled by tracking the individual drug particles within the airways until 
they deposit or are exhaled. Inertial impaction, gravitational settling and thermal diffusion 
deposition mechanisms were considered. Deposition computations in the upper airways were 
based on empirical formulas (Cheng 2003). The tracheobronchial part of the haefelairways was 
modelled based on the database of Raabe et his co-workers containing morphometrical 
parameters such as tube lengths and diameters and branching and gravity angles. The geometry 
of the acinar airways was based on the data (Haefeli-Bleuer and Weibel, 1988). The numerical 
deposition model was validated for the case of medical aerosols in our earlier works (e.g. Farkas 
et al. 2016; Farkas et al. 2017). The inputs of the model were the size distributions of the drugs 
measured in this work by cascade impactor techniques and the inhalation profile of a COPD 
patient when inhaling through Breezhaler® derived from the work (Colthorpe et al. 2013). This 
profile (patient 7 in the work (Colthorpe et al. 2013)) characterized by an inhaled volume of 
1700 ml and inhalation time of 3.2 s was chosen because the corresponding flow rate fits well 
with the flow rate through the impactor applied by us for the determination of particle size 
distributions (30 L/min). It is worth noting that since the drugs are emitted by a DPI, both the 
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emitted dose and particle size distribution would be different at another flow rate. 
3. Results and discussion  
3.1 Structural investigations  
By X-ray (XRPD) we obtained useful information about the excipients and particle engineered 
materials for DPI formulation. The knowledge of the solid state form (crystalline/amorphous 
character) of CIP in the product can be determinative in terms of aerodynamic behavior, 
efficiency, compatibility with excipients and stability of drug formulation during storage. 
To evaluate the patterns of the excipients (Figure 2., upper part) we can conclude that MgSt 
(3.8 and 5.5 2Theta degree) and NaSt (4.0 and 6.0 2Theta degree) are crystalline materials. IH 
70 is crystalline with 12.8, 16.8 and 20.0 2Theta degree, which solid state form did not change 
after its surface modification using 4h mixing. However, the low concentration of MgSt did not 
appear on the XRPD pattern of IH 70_MgSt, which means that the produced thin film of MgSt 
covered the surface of IH 70. According to the literature (Byrn et al. 2017), the lactose particles 
can be broken by mechanical forces (e.g. mixing for a long time) and this can result in a decrease 
in crystallinity. We concluded that the crystallinity of IH 70 was the same as before the surface 
modification. 
Based on the results of XRPD (Figure 2., lower part), the crystalline character of untreated µCIP 
can be seen. The fingerprint shows a number of typical peak intensities that exhibit high 
crystallinity, pattern with peak intensity at 8.2, 9.5, 19.22, 26.39 and 29.16 2Theta degree. 
During the preparation of the carrier-based system (µCIP+IH70), the crystalline character of 
CIP and IH 70 was retained. However, in the case of the carrier-free system (CIP_0.5NaSt_spd), 
the amorphous nature of CIP could be detected by the presence of NaSt and using the spray 
drying method. We observed the same amorphous character if CIP and the crystalline state of 
IH70_MgSt produced the novel DPI by the combined technology 
(CIP_0.5NaSt_spd+IH70_MgSt). 
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Figure 2. XRPD pattern of excipients and applied CIP for DPI formulations 
3.2 Evaluation of the micrometric properties 
The individual surface properties, the morphology of the raw materials, as well as the 
distribution of the CIP on the surface of the carrier were investigated by SEM pictures (Fig. 3.). 
The analyses of IH 70 revealed large, smooth, prismatic, nearly rhomboid particles in the image. 
We concluded that µCIP showed small crystals with an irregular shape. The surface of IH70 
had more active places offering insertions for the microsized drug particles, which presented 
uniform distribution on the surface (µCIP+IH70). Spray dried samples contained monodisperse 
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particles with spherical morphology with surface roughness. A small amount of NaSt could 
help to produce individual particles (CIP_0.5NaSt_spd). In the case of the combined 
technology, the presence of MgSt covered the active places on the surface of IH70, presenting 
a smooth area. Therefore the spherical particles concentrated in the cavities had heterogeneous 
distribution. 
 
Figure 3. The morphology of raw IH70, µCIP and the carrier-based, carrier-free, novel 
DPI formulations 
Based on the results of particle size analyses (shown in Table 3.) it could be seen that IH 70 
consisted of large particles (215 µm ) and the presence of MgSt with a 4h smoothing procedure 
broke down the particles slightly and also increased the density of the carrier. µCIP particles 
are in a range between 2-15 µm, they do not fully meet the size range requirement (1-5 µm) for 
inhalation therapy, but the mean size is around 5 µm. Spray drying modified the size to be 
favourable (1-5 µm). The determination of bulk density was determinative for µCIP and 
CIP_0.5NaSt_spd because only the small drug particles will be deposited in the lung. We 
conclude that one-fourth density value can be achieved by particle engineering, which can offer 
improved aerodynamic properties for co-spray dried samples.  
Table 3. Particle size distribution and bulk density of the samples 
 
D0.1 
[µm] 
D0.5 
[µm] 
D0.9 
[µm] 
Bulk density 
[g/cm3] 
IH70 135.02 215.00 305.34 0.600 
IH70_MgSt 71.48 174.32 286.01 0.7474 
µCIP 2.09 5.05 14.55 0.4192 
µCIP+IH70 25.55 170.36 319.90 - 
CIP_0.5NaSt_spd 1.15 2.24 4.55 0.1459 
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CIP_0.5NaSt_spd+IH70_MgSt 3.25 128.76 194.18 - 
- not measurable 
 
3.3 In vitro aerodynamic measurement 
The aerodynamic characteristics were measured at 28.3 L/min flow rates. Table 4. shows the 
median mass aerodynamic diameter (MMAD) values, fine particle fraction (FPF) as well as the 
emitted dose (ED). The carrier-based formulation is correlated with the marketed products. 
With 7-9 µm MMAD value only 23-24 % FPF was produced. It means the drug will be 
deposited in the upper bronchial part of the lung. The carrier-free system, CIP_0.5NaSt_spd 
could be characterized by improved aerodynamic properties (FPF: 48-54 %). It means that the 
modified habit is more favourable than the irregular microsized CIP on the carrier. The novel 
combination method presented the lowest MMAD (around 3 µm). Because of the 63.75 % FPF 
(< 5 µm) and 39.22 % FPF (< 3 µm) this novel formulation method offers an effective CIP dose 
in the deeper alveolar part of the lung, where the liquidation of a bacterial biofilm is very 
important. The ED by all of the samples were also high (around 90%), indicating a favourably 
weak adhesive character between the powder and the capsule. 
Table 4. Parameters determining in vitro lung deposition 
Samples 
MMAD  
(µm) 
FPF (%) 
< 5 µm 
FPF (%) 
< 3 µm 
ED 
(%) 
µCIP +IH70 7.9±0.10 23.30±0.23 11.88±0.20 96.92±0.11 
CIP_0.5NaSt_spd 4.14±0.18 54.27±2.75 27.14±2.38 76.99±3.32 
CIP_0.5NaSt_spd+IH70_MgSt 3.47±0.02 63.75±1.21 39.22±0.74 90.45±1.80 
 
3.4 In silico assessment for prediction particle deposition in the lung 
The breathing parameter values needed for the in silico simulations were: 1.7 L, 3.2 s and 5, 10 
s for the inhaled volume, inhalation time and breath-hold time, respectively. These values 
correspond to a mean inhalation flow rate of 31.9 L/min. The in silico analyses were applied 
for the best DPI products including carrier-based, carrier-free and combined formulations. The 
results of the deposition simulations are shown in Figure 5. It is worth noting that all dose values 
in Figure 4. are expressed as a percent of drug dose metered in the capsule. We conclude that 
the deposition results of in vitro and in silico investigations using a 5s breath-hold time exhibit 
the same tendency. The in silico deposition pattern for the carrier-based formulation contains a 
high extrathoracic dose fraction because of the significant number of large particles, which 
deposit by impaction mostly in the throat region. A high fraction of the particles are also 
exhaled, while lung deposition is the lowest for this formulation. For the carrier-free 
formulation, the deposition profile was much more convenient with a dose fraction of around 
48 % in the lung and a dose fraction of 12 % as the exhaled amount. However, when using the 
combined procedure, the dose fraction in the lung was as high as 55 %. To assess the effect of 
the length of breath-holding after the inhalation of the drug, we calculated the regional 
deposited dose fractions also for a 10s breath-hold time. Figure 4. demonstrates that longer 
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breath-hold results in higher lung doses and lower exhaled doses for all formulations. It means 
that with the special inhalation technique drug deposition can be further improved and the 
exhaled amount of drug kept at a minimum level, especially in the case of carrier-free samples 
and samples prepared by the combined method. 
 
  
Figure 4. Comparison of the three formulation methods in silico by different breath-
hold (BH) times (ET: extrathoracic airways, LUNG: bronchial and acinar parts, EXH: 
exhalation fraction) 
 
 
3.5 The effect of interparticle interactions on aerodynamic properties 
The effectiveness of the novel DPI formulation developed with the combined technology can 
be related to the interparticle interactions between components, which modify the balance of 
cohesive and adhesive forces. 
Without surface modification (Figure 5A) a microporous (pore diameter 1-10 µm), by surface 
treatment (Figure 5B) a macroporous (pore diameter above 10 µm) surface of the applied IH70 
could be found (Shalas et al., 2015). This also explains the phenomenon of the spread of 
different active substances. Therefore nearly homogeneous distribution was reached after 
blending µCIP particles with IH70 (Figure 5A). Electron microscopic images (Figure 5B) were 
also made to study how MgSt affects the surface of the carrier and thus its role in the DPI 
formulation. It was found that MgSt modified (by thin film forming) the active sites of the 
carrier and thus altered the surface of the drug carrier, thereby presumably affecting the 
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interparticle interactions. The spray-dried particles centered to different parts of the smoothed 
carrier because of the presence of MgSt. 
 
 
 
 Figure 5. Schematic interpretation of µCIP and IH70 after blending (A) and the 
effect of MgSt-modification on the distribution of co-spray dried CIP (B) 
During DPI formulation, two types of interactions should be critical factors, drug-drug cohesive 
forces (carrier-free formulation) and drug-carrier adhesive forces (carrier-based formulation). 
First, contact angle measurements were performed to calculate the polarity characteristic of the 
materials and cohesive work (Wc) that can be interpreted between particles of the same quality. 
The lipophilic components (MgSt and NaSt) affected polarity and cohesivity. The highest 
polarity values were obtained with crystalline µCIP. Concerning the results of cohesion work 
(Wc), it can be stated that in the case of CIP_spd, cohesivity decreased between the spherical, 
rough particles and the presence of NaSt could also contribute to the decrease in Wc. This could 
be the main reason for the topicality of carrier-free systems because the special morphology 
and the lower cohesivity of particles could result in better deposition properties. As described 
in the Methods part, we determined the work and force of adhesion and the spreading coefficient 
(see Table 5.) for the blended products. It can be stated that MgSt reduced the work and force 
of adhesion (anti-adhesive excipient) and decreased the spreadability of the drug on the surface 
(a high S value means less spreadability). It was found that the adhesion force in the novel 
formulated products containing the spray dried drug and the surface modified IH70 was 
considerably lower than in about one-third of the carrier-based samples containing µCIP. 
 
Table 5. Evaluation of adhesive-cohesive balance 
Samples Wc [mN/m] 
Wadh 
[mN/m] 
Fadh 
[mN] S21 
µCIP 161.60 - - - 
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µCIP+IH70 - 108.26 1.690*10-3 1.64 
CIP_0.5NaSt_spd 123.26 - - - 
CIP_0.5NaSt_spd+IH70_MgSt - 72.57 0.504*10
-3
 
-19.06 
 
As a summary of interparticle interactions, we conclude that adhesion is strong between µCIP 
and IH70 by blending, which resulted in an FPF value of only 23 % with low lung deposition. 
We observed that co-spray-drying with NaSt decreased cohesivity, the FPF of the carrier-free 
formulation was almost high (54 %). The novel combined technology could offer less 
cohesivity and adhesivity, therefore aerodynamic behaviour improved. With the use of MgSt, 
polarity, the work of adhesion and the force of adhesion decreased, thus spreading became less 
favourable. Therefore the interparticle interactions were modified, the drug may be easier to 
detach from the surface of the carrier during inhalation with FPF around 63%. 
5. Conclusion 
Thanks to their beneficial properties, dry powder inhalers (DPI) can have an important role in 
drug formulation as compared with Nebulizers and pressurized metered dose inhalers. The 
purpose of our research work was the development of a novel antibiotic-containing DPI 
including the advantages of carrier-based and carrier-free formulations. The samples containing 
ciprofloxacin hydrochloride (CIP), lipophilic additive (NaSt), surface modifier (MgSt) and 
inhalable carrier (IH70) were characterized. Based on the comparison of the results we 
concluded that cohesive-adhesive balance could be modified with the particle engineering of 
the drug and the presence of the excipients. Therefore we offer a new possibility in DPI 
formulation to improve the in vitro-in silico aerodynamic properties. The in silico deposition 
results were in line with the in vitro measurements and yielded increased lung doses for the 
sample prepared by the combination method. The present work demonstrates that the novel 
procedure for the formulation of CIP-DPI offers a more effective therapy for cystic fibrosis 
with deeper deposition of the drug. 
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